AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32506428 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological senescence group
Number of subjects: 1002
Study 32506485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell surface vimentin (CSV) positive circulating tumor cells (CTC) monitoring
Number of subjects: 93
Study 32506695 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with golimumab
Number of subjects: 102
Study 32506695 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with golimumab
Number of subjects: 102
Study 32507018 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-Duplex Ultrasound (DUS)
Number of subjects: 539
Study 32507018 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography-Aortography (CTA)
Number of subjects: 539
Study 32507378 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCESS integrated care for patients with severe psychotic disorders
Number of subjects: 312
Study 32507378 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with substance dependence
Number of subjects: 312
Study 32507378 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCESS integrated care
Number of subjects: 312
Study 32507378 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid substance use dependence
Number of subjects: 312
Study 32507565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dorsal penile nerve block (DPNB)
Number of subjects: 26
Study 32507565 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural block (CEB)
Number of subjects: 26
Study 32507584 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-child formula (YCF) consumption after age 10 months
Number of subjects: 561
Study 32507584 — intervention group
Group type: EXPERIMENTAL
Intervention: Current YCF consumption at age 24 months
Number of subjects: 561
Study 32507584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged YCF consumption (>12 months)
Number of subjects: 561
Study 32507584 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing daily volume of YCF consumed at age 24 months
Number of subjects: 561
Study 32507584 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or past YCF use
Number of subjects: 561
Study 32507854 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIRI plus mFOLFOX6
Number of subjects: 57
Study 32507905 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (PoCUS) for hydronephrosis
Number of subjects: 413
Study 32508029 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg + gefitinib 250 mg (Cohort A)
Number of subjects: 13
Study 32508029 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 250 mg + gefitinib 250 mg (Cohort B)
Number of subjects: 13
Study 32508063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab with methotrexate
Number of subjects: 0
Study 32508063 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 32508188 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities Scale for Kids Performance
Number of subjects: 0
Study 32508541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 31
Study 32508541 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adenosine
Number of subjects: 31
Study 32508541 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (single bolus dose)
Number of subjects: 31
Study 32508818 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIV) of rhIL-15 at 2 mcg/kg/day
Number of subjects: 0
Study 32509320 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovering Together (RT) intervention
Number of subjects: 20
Study 32509320 — intervention group
Group type: COMPARATOR
Intervention: Minimally Enhanced Usual Care (MEUC)
Number of subjects: 20
Study 32509319 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva assist device
Number of subjects: 34
Study 32509319 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 34
Study 32509322 — intervention group
Group type: EXPERIMENTAL
Intervention: GP_Posit intervention
Number of subjects: 0
Study 32509322 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 32509392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib with celecoxib (SoraCele)
Number of subjects: 116
Study 32509392 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 116
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian maternal ethnicity
Number of subjects: 1851
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: West Asian/North African maternal ethnicity
Number of subjects: 1851
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: East Asian maternal ethnicity
Number of subjects: 1851
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer breastfeeding duration
Number of subjects: 1851
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cow's milk intake >2 cups
Number of subjects: 1851
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: Current infant formula use
Number of subjects: 1851
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle use beyond 15 months
Number of subjects: 1851
Study 32509978 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat consumption
Number of subjects: 1851
Study 32510046 — intervention group
Group type: EXPERIMENTAL
Intervention: High load treatment
Number of subjects: 72
Study 32510046 — intervention group
Group type: COMPARATOR
Intervention: Low load treatment
Number of subjects: 72
Study 32511251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1,000 mg) infusion on the first day of treatment
Number of subjects: 92
Study 32511251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1,000 mg) infusion
Number of subjects: 92
Study 32511514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized in-line endotracheal dornase alfa co-administered with albuterol
Number of subjects: 5
Study 32511534 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of Nitric Oxide (NO)
Number of subjects: 0
Study 32511534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhalation of NO)
Number of subjects: 0
Study 32511695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capsulized fecal microbiota transplantation (FMT) for 2 days
Number of subjects: 15
Study 32511695 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-FMT antibiotics
Number of subjects: 15
Study 32511695 — intervention group
Group type: EXPERIMENTAL
Intervention: CPE carriers who achieved eradication
Number of subjects: 15
Study 32511695 — intervention group
Group type: EXPERIMENTAL
Intervention: CPE carriers who failed treatment
Number of subjects: 15
Study 32511794 — intervention group
Group type: EXPERIMENTAL
Intervention: Papilla-related variables (morphology)
Number of subjects: 658
Study 32511983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab plus lenalidomide
Number of subjects: 81
Study 32512291 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (titrated to blood pressure up to a maximum of 160 mg bid)
Number of subjects: 651
Study 32512291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 651
Study 32512539 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity secondary to stroke at 6 months
Number of subjects: 500
Study 32512539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes, cognitive and functional assessments
Number of subjects: 500
Study 32512539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline, 3-month, and 6-month assessments
Number of subjects: 500
Study 32512806 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) levels
Number of subjects: 579
Study 32513113 — intervention group
Group type: EXPERIMENTAL
Intervention: VPIA analgesic infusion pump
Number of subjects: 19
Study 32513121 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity measured by an ankle mounted pedometer for 5 days, and physical tests measuring strength, balance, and walking speed.
Number of subjects: 0
Study 32513121 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires assessing various factors related to fall risk.
Number of subjects: 0
Study 32513178 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care with advanced cardiac imaging including echocardiography with deformation analysis and cardiovascular magnetic resonance (CMR) with T1 parametric mapping before and after AVR.
Number of subjects: 0
Study 32513178 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical AVR with myocardial biopsy for histological validation.
Number of subjects: 0
Study 32513204 — intervention group
Group type: EXPERIMENTAL
Intervention: Included patients (70 patients)
Number of subjects: 279
Study 32513204 — intervention group
Group type: COMPARATOR
Intervention: Omitted patients (204 patients)
Number of subjects: 279
Study 32513204 — intervention group
Group type: COMPARATOR
Intervention: Reasons for omission
Number of subjects: 279
Study 32513578 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor identification test in Ob patients
Number of subjects: 420
Study 32513578 — intervention group
Group type: COMPARATOR
Intervention: Flavor identification test in NW subjects
Number of subjects: 420
Study 32513578 — intervention group
Group type: COMPARATOR
Intervention: Flavor identification test in OW subjects
Number of subjects: 420
Study 32513801 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 40 mg/kg/dose every 8 hours as a 4-hour infusion
Number of subjects: 57
Study 32513801 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 110 mg/kg/day as a continuous infusion
Number of subjects: 57
Study 32514369 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Summer Learners (HSL) program
Number of subjects: 180
Study 32514369 — intervention group
Group type: COMPARATOR
Intervention: 21C (control group)
Number of subjects: 180
Study 32514382 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Game (SG) designed for nurse training
Number of subjects: 71
Study 32514382 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Game (SG)
Number of subjects: 71
Study 32514439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus prednisone
Number of subjects: 57
Study 32514439 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine plus prednisone
Number of subjects: 57
Study 32514450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 (SGLT2) inhibitors for 12 weeks
Number of subjects: 0
Study 32514599 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AKI
Number of subjects: 1545
Study 32514599 — intervention group
Group type: COMPARATOR
Intervention: Transient AKI
Number of subjects: 1545
Study 32514670 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case robotic partial nephrectomy (RPN)
Number of subjects: 82
Study 32514794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) 3 mg
Number of subjects: 66
Study 32514794 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon (IMG) 1 mg
Number of subjects: 66
Study 32514886 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA (200 mg/kg intraperitoneal)
Number of subjects: 20
Study 32514886 — intervention group
Group type: EXPERIMENTAL
Intervention: SWIG (5 mg/kg intravenous)
Number of subjects: 20
Study 32514886 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA (20 mg/kg oral)
Number of subjects: 20
Study 32514886 — intervention group
Group type: EXPERIMENTAL
Intervention: SWIG (2.5 mg/kg intravenous)
Number of subjects: 20
Study 32514886 — intervention group
Group type: COMPARATOR
Intervention: SWIG and 5-ALA
Number of subjects: 20
Study 32514905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocephalus after ICH
Number of subjects: 1342
Study 32514905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocephalus (≤ 3 days)
Number of subjects: 1342
Study 32514905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocephalus (4-13 days)
Number of subjects: 1342
Study 32514905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocephalus (≥ 14 days)
Number of subjects: 1342
Study 32514905 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality in ICH patients with hydrocephalus
Number of subjects: 1342
Study 32514905 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable outcome in patients with hydrocephalus
Number of subjects: 1342
Study 32514905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause of death in patients with hydrocephalus
Number of subjects: 1342
Study 32514990 — intervention group
Group type: EXPERIMENTAL
Intervention: CBW/CBW
Number of subjects: 12
Study 32514990 — intervention group
Group type: EXPERIMENTAL
Intervention: OW/CBW
Number of subjects: 12
Study 32514990 — intervention group
Group type: EXPERIMENTAL
Intervention: CBW
Number of subjects: 12
Study 32514990 — intervention group
Group type: EXPERIMENTAL
Intervention: OW
Number of subjects: 12
Study 32514990 — intervention group
Group type: EXPERIMENTAL
Intervention: CBW/OW
Number of subjects: 12
Study 32514990 — intervention group
Group type: EXPERIMENTAL
Intervention: OW/OW
Number of subjects: 12
Study 32514990 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 12
Study 32515118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 32515118 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32515286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics service led by pharmacists
Number of subjects: 0
Study 32515349 — intervention group
Group type: EXPERIMENTAL
Intervention: 'agonist-only' Activin A muteins that activate ACVR1B but cannot form the non-signaling complex (NSC) with ACVR1
Number of subjects: 0
Study 32515349 — intervention group
Group type: COMPARATOR
Intervention: Control group (wild-type ACVR1)
Number of subjects: 0
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia screening
Number of subjects: 151
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysarthria screening
Number of subjects: 151
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia screening
Number of subjects: 151
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate binary logistic regression for dysphagia
Number of subjects: 151
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate binary logistic regression for dysarthria
Number of subjects: 151
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate binary logistic regression for aphasia
Number of subjects: 151
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted risk for aphasia
Number of subjects: 151
Study 32515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia association with stroke etiology
Number of subjects: 151
Study 32515679 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted PET tracer zirconium 89
Number of subjects: 0
Study 32515748 — intervention group
Group type: EXPERIMENTAL
Intervention: GUM intervention (integrated physical activity and psychosocial program)
Number of subjects: 101
Study 32516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32516091 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Cisplatin
Number of subjects: 0
Study 32516228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative presepsin measurement
Number of subjects: 222
Study 32516228 — intervention group
Group type: COMPARATOR
Intervention: Basic risk model (revised cardiac risk index, high-sensitive cardiac troponin T, N-terminal fragment of pro-brain natriuretic peptide)
Number of subjects: 222
Study 32516228 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic risk model + presepsin
Number of subjects: 222
Study 32516377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg, 3 courses)
Number of subjects: 112
Study 32516414 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD followed by BV consolidation
Number of subjects: 41
Study 32516641 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic secretion (SS) cultures
Number of subjects: 109
Study 32516757 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb exoskeleton training for four weeks
Number of subjects: 6
Study 32517405 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 20 mL of 0.5% plain bupivacaine
Number of subjects: 18
Study 32517690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids and hormone replacement
Number of subjects: 1
Study 32517690 — intervention group
Group type: EXPERIMENTAL
Intervention: FDS (sensitive radiotracer for bacterial infections)
Number of subjects: 1
Study 32517690 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 1
Study 32517727 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVE intervention with a municipal coordinator facilitating Learning, Innovation, Volunteering, and Empowerment (LIVE) over a 6-month period.
Number of subjects: 315
Study 32517727 — intervention group
Group type: COMPARATOR
Intervention: Control group (dyads waiting for the intervention).
Number of subjects: 315
Study 32517834 — intervention group
Group type: EXPERIMENTAL
Intervention: DietCam
Number of subjects: 30
Study 32518208 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT >50 ng/L
Number of subjects: 1642
Study 32518208 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score ≥7
Number of subjects: 1642
Study 32518208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hs-cTnT >50 ng/L and a second independent predictor
Number of subjects: 1642
Study 32518419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (Rux) - Janus Kinase 1/2 inhibitor, administered with efficacy/toxicity guided step up dosing up to 14 days
Number of subjects: 105
Study 32518518 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, person-centred, health-promoting follow-up programme (includes two telephone calls and three visits to a vascular nurse in the first year after surgical treatment)
Number of subjects: 0
Study 32518518 — intervention group
Group type: COMPARATOR
Intervention: Standard care (visit to a vascular surgeon 4-8 weeks after surgery and a visit to the outpatient clinic 1 year after surgical treatment)
Number of subjects: 0
Study 32518518 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, person-centred, health-promoting follow-up programme
Number of subjects: 0
Study 32518518 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 32518597 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroidal aromatase inhibitors
Number of subjects: 0
Study 32518597 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal aromatase inhibitors
Number of subjects: 0
Study 32518655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) (85-95% of peak effort)
Number of subjects: 28
Study 32518655 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 28
Study 32518655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 28
Study 32518670 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a six-week mindfulness intervention
Number of subjects: 11
Study 32518674 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement pattern training (MoveTrain)
Number of subjects: 46
Study 32518674 — intervention group
Group type: COMPARATOR
Intervention: Standard strengthening and flexibility
Number of subjects: 46
Study 32518833 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cohort (three initial monthly IVT-AFL injections and ≥6 injections)
Number of subjects: 593
Study 32518833 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular cohort with three initial monthly injections
Number of subjects: 593
Study 32518833 — intervention group
Group type: COMPARATOR
Intervention: Irregular cohort without three initial monthly injections
Number of subjects: 593
Study 32518833 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (all patients)
Number of subjects: 593
Study 32518833 — intervention group
Group type: COMPARATOR
Intervention: Regular cohort vs irregular cohort without three initial monthly injections
Number of subjects: 593
Study 32518833 — intervention group
Group type: COMPARATOR
Intervention: Irregular cohort with three initial monthly injections vs irregular cohort without three initial monthly injections
Number of subjects: 593
Study 32518861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan modified-release (MR) 120 mg
Number of subjects: 24
Study 32518861 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan immediate-release (IR) 90+30 mg
Number of subjects: 24
Study 32518861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR (various doses 20 to 120 mg)
Number of subjects: 24
Study 32518861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR and IR
Number of subjects: 24
Study 32518862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR 50 mg once daily
Number of subjects: 177
Study 32518862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR 80 mg once daily
Number of subjects: 177
Study 32518862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan IR 60/30 mg daily split dose
Number of subjects: 177
Study 32518862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 32518891 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent split, inactivated influenza vaccine (TIV) 0.5 ml (15 µg of hemagglutinin per strain)
Number of subjects: 480
Study 32518891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Number of subjects: 480
Study 32519336 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO-enrolled children
Number of subjects: 0
Study 32519336 — intervention group
Group type: COMPARATOR
Intervention: Non-ACO managed care plans (control group)
Number of subjects: 0
Study 32519518 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by DICEP regimen (Dexamethasone, ifosfamide, cisplatin, etoposide, and pegaspargase)
Number of subjects: 30
Study 32519518 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by DICEP regimen
Number of subjects: 30